Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection

Transplantation

Volumn 68, Issue 2, 1999, Pages 310-313

  Hengster, Paul ^a   Pescovitz, Mark D ^a   Hyatt, Debra ^b   Margreiter, Raimund ^c   Bäckman, Lars ^d   Berthoux, Francois ^e   Bradley, Andrew ^f   Bumgardner, Ginny ^g   Burdick, James ^d   Cambi, Vincenzo ^h   Chan, Gary ⁱ   Charpentier, Bernard ^j   Daloze, Pierre ^g   Ekberg, Henrik ^k   Gannedahl, Göran ^l   Gaston, Robert ^m   Halloran, Phillip ^ae   Hardie, Ian ⁿ   Hauser, Ingeborg ^o   Johnson, Robert ^p   Keown, Paul ^q   Kessler, Michèle ^r   Kiberd, Bryce ^s   Kirkman, Robert ^t   Lazarovits, Andrew ^u   Matas, Arthur J ^j   Mühlbacher, Ferdinand ^v   Nashan, Bjorn ^d   Neylan, John ^w   Persson, Nils ^j   Pescovitz, Mark ^j   Piccoli, Guiseppe ^x   Pichlmayr, Rudolf ^d   Ponticelli, Claudio ^y   Rodgers, Stuart ^z   Shapiro, Michael E ^aa   Tiller, David ^ab   Tufveson, Gunnar ^ac   Tyden, Gunnar ^v   Vanrentergehm, Yves ^aa   Vercellone, Antonio ^ac   Vialtel, Paul ^w   Vincenti, Flavio ^ad   Weinstein, Samuel ^h   Wilkinson, Alan ^ab   more..

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c HÔPITAL NORD   (France)

^d OHIO STATE UNIVERSITY   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

^f UNIVERSITY OF PARMA   (Italy)

^g TAMPA GENERAL HOSPITAL   (United States)

^h BICÊTRE HOSPITAL   (France)

ⁱ NOTRE DAME HOSPITAL   (Canada)

^j UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^k PRINCESS ALEXANDRA HOSPITAL   (Australia)

^l KLINIKUM NÜRNBERG   (Germany)

^m MANCHESTER ROYAL INFIRMARY   (United Kingdom)

ⁿ VANCOUVER GENERAL HOSPITAL   (Canada)

^o CHU NANCY BRABOIS   (France)

^p QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^q BRIGHAM AND WOMEN S HOSPITAL   (United States)

^r LONDON HEALTH SCIENCES CENTRE   (Canada)

^s UNIVERSITY OF MINNESOTA   (United States)

^t MEDICAL UNIVERSITY OF VIENNA   (Austria)

^u EMORY UNIVERSITY HOSPITAL   (United States)

^v INDIANA UNIVERSITY   (United States)

^w FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^x BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^y ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^z KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^aa UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^ab GRENOBLE UNIVERSITY HOSPITAL   (France)

^ac UNIVERSITY OF CALIFORNIA   (United States)

^ad UNIVERSITY OF CALIFORNIA   (United States)

^ae NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; IMMUNOGLOBULIN G; INTERLEUKIN 2 RECEPTOR ANTIBODY; MEPREDNISONE; OKT 3; PLACEBO; PREDNISONE; STEROID; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY GRAFT REJECTION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK;

ADULT; ANTIBODIES, MONOCLONAL; CYTOMEGALOVIRUS INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; RECEPTORS, INTERLEUKIN-2;

EID: 0033609459     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199907270-00028     Document Type: Article

References (7)

1. Boyce NW, Hayes K, Gee D, et al. Cytomegalovirus infection complicating renal transplantation and its relationship to acute transplant glomerulopathy. Transplantation 1988; 45: 706.
2. Bia MJ, Andiman W, Gaudio K, et al. Effect of treatment with cyclosporine versus azathioprine on incidence and severity of cytomegalovirus infection posttransplantation. Transplantation 1985; 40: 610.
3. Gulanikar AC, MacDonal AS, Sungurtekin U, Belitsky P. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation 1992; 53: 323.
4. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55: 993.
5. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin-2 receptor. Proc Natl Acad Sci USA 1989; 86: 10029.
6. Vincenti F, Kirkman R, Light S, et al. Interleukin 2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161.
7. Nashan B, Hardie IR, Lin A, et al. Reduction of acute renal allograft rejection by daclizumab. Daclizumab double therapy study group. Transplantation 1999; 67: 110.